AR123855A1 - PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE - Google Patents

PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE

Info

Publication number
AR123855A1
AR123855A1 ARP210102890A ARP210102890A AR123855A1 AR 123855 A1 AR123855 A1 AR 123855A1 AR P210102890 A ARP210102890 A AR P210102890A AR P210102890 A ARP210102890 A AR P210102890A AR 123855 A1 AR123855 A1 AR 123855A1
Authority
AR
Argentina
Prior art keywords
cdr
seq
amino acid
acid sequence
peg
Prior art date
Application number
ARP210102890A
Other languages
Spanish (es)
Inventor
Wei Liang
- Lin Weiyu Ching
Yan Wu
Minhong Yan
Breanna Sachiko Vollmar
Mingjian Fei
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR123855A1 publication Critical patent/AR123855A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Reivindicación 1: Un anticuerpo PEGilado que se une a MerTK, en donde el anticuerpo está conjugado con uno o más polímeros de polietilenglicol (PEG); en donde cada uno de los polímeros de PEG está conjugado con una cadena pesada o cadena liviana del anticuerpo en un residuo de cisteína modificada por ingeniería genética; y en donde el anticuerpo comprende: (1) un dominio variable de la cadena pesada (VH) que comprende (a) una CDR-H1 que comprende la secuencia de aminoácidos de SYAMG (SEQ ID Nº 1), (b) una CDR-H2 que comprende la secuencia de aminoácidos de IINSYGNTYYANWAKG (SEQ ID Nº 2), y (c) una CDR-H3 que comprende la secuencia de aminoácidos de DPGVSSNL (SEQ ID Nº 3), y un dominio variable de la cadena liviana (VL) que comprende (d) una CDR-L1 que comprende la secuencia de aminoácidos de QASQNIYSGLA (SEQ ID Nº 4), (e) una CDR-L2 que comprende la secuencia de aminoácidos de GASKLAS (SEQ ID Nº 5), y (f) una CDR-L3 que comprende la secuencia de aminoácidos de QATYYSSNSVA (SEQ ID Nº 6); o (2) un dominio variable de la cadena pesada (VH) que comprende (a) una CDR-H1 que comprende la secuencia de aminoácidos de ANTMN (SEQ ID Nº 7), (b) una CDR-H2 que comprende la secuencia de aminoácidos de IFTATGSTYYATWVNG (SEQ ID Nº 8), y (c) una CDR-H3 que comprende la secuencia de aminoácidos de SGSGSSSGAFNI (SEQ ID Nº 9), y un dominio variable de la cadena liviana (VL) que comprende (d) una CDR-L1 que comprende la secuencia de aminoácidos de QASQSISSSLA (SEQ ID Nº 10), (e) una CDR-L2 que comprende la secuencia de aminoácidos de AASILAS (SEQ ID Nº 11), y (f) una CDR-L3 que comprende la secuencia de aminoácidos de QCTSYGSLFLGP (SEQ ID Nº 12).Claim 1: A PEGylated antibody that binds MerTK, wherein the antibody is conjugated to one or more polyethylene glycol (PEG) polymers; wherein each of the PEG polymers is conjugated to an antibody heavy chain or light chain at an engineered cysteine residue; and wherein the antibody comprises: (1) a heavy chain (VH) variable domain comprising (a) a CDR-H1 comprising the SYAMG amino acid sequence (SEQ ID NO: 1), (b) a CDR- H2 comprising the amino acid sequence of IINSYGNTYYANWAKG (SEQ ID NO 2), and (c) a CDR-H3 comprising the amino acid sequence of DPGVSSNL (SEQ ID NO 3), and a light chain (VL) variable domain. comprising (d) a CDR-L1 comprising the amino acid sequence of QASQNIYSGLA (SEQ ID NO: 4), (e) a CDR-L2 comprising the amino acid sequence of GASKLAS (SEQ ID NO: 5), and (f) a CDR-L3 comprising the amino acid sequence of QATYYSSNSVA (SEQ ID NO: 6); or (2) a heavy chain (VH) variable domain comprising (a) a CDR-H1 comprising the amino acid sequence of ANTMN (SEQ ID NO: 7), (b) a CDR-H2 comprising the sequence of amino acids of IFTATGSTYYATWVNG (SEQ ID NO: 8), and (c) a CDR-H3 comprising the amino acid sequence of SGSGSSSGAFNI (SEQ ID NO: 9), and a light chain (VL) variable domain comprising (d) a CDR-L1 comprising the amino acid sequence of QASQSISSSLA (SEQ ID No. 10), (e) a CDR-L2 comprising the amino acid sequence of AASILAS (SEQ ID No. 11), and (f) a CDR-L3 comprising the amino acid sequence of QCTSYGSLFLGP (SEQ ID NO: 12).

ARP210102890A 2020-10-20 2021-10-19 PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE AR123855A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063094197P 2020-10-20 2020-10-20

Publications (1)

Publication Number Publication Date
AR123855A1 true AR123855A1 (en) 2023-01-18

Family

ID=78725615

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102890A AR123855A1 (en) 2020-10-20 2021-10-19 PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE

Country Status (3)

Country Link
AR (1) AR123855A1 (en)
TW (1) TW202233671A (en)
WO (1) WO2022086957A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024148175A1 (en) * 2023-01-05 2024-07-11 Opus Genetics Inc. Gene therapy for ocular disease

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US830930A (en) 1905-11-22 1906-09-11 E & T Fairbanks & Co Weighing-scale.
US1624821A (en) 1926-03-26 1927-04-12 Sidney C Ashton Oil-well pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
ATE503496T1 (en) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic BIOSYNTHETIC BINDING PROTEIN FOR TUMOR MARKERS
PL174721B1 (en) 1992-11-13 1998-09-30 Idec Pharma Corp Monoclonal antibody anty-cd2
JPH08511420A (en) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド Body
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2246069T3 (en) 1997-05-02 2006-02-01 Genentech, Inc. PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PT994903E (en) 1997-06-24 2005-10-31 Genentech Inc METHODS AND COMPOSITIONS FOR GALACTOSILED GLICOPROTEINS
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69840412D1 (en) 1997-10-31 2009-02-12 Genentech Inc METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
ATE375365T1 (en) 1998-04-02 2007-10-15 Genentech Inc ANTIBODIES VARIANTS AND FRAGMENTS THEREOF
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (en) 1998-04-20 2018-01-18 Roche Glycart Ag Antibody glycosylation engineering to improve antibody-dependent cell cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU6117000A (en) 1999-07-26 2001-02-13 Genentech Inc. Novel polynucleotides and method of use thereof
KR100797667B1 (en) 1999-10-04 2008-01-23 메디카고 인코포레이티드 Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2403425C (en) 2000-04-11 2013-08-27 Genentech, Inc. Multivalent antibodies and uses therefor
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
PL213948B1 (en) 2001-10-25 2013-05-31 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR20050000380A (en) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 Cells with modified genome
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
WO2004003192A1 (en) 2002-06-28 2004-01-08 Bayer Healthcare Ag Human receptor tyrosine kinase mertk
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2264152B1 (en) 2003-01-22 2015-05-20 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
KR100891620B1 (en) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
PT1871805T (en) 2005-02-07 2019-12-02 Roche Glycart Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
EP2439272A3 (en) 2005-05-09 2013-07-31 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
ES2639857T3 (en) 2008-02-11 2017-10-30 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
KR20240093808A (en) 2008-12-09 2024-06-24 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2225932B1 (en) 2009-03-03 2013-01-23 Institut de Recherche pour le Développement ( IRD) Method for enhancing market garden plant growth
KR101431318B1 (en) 2009-04-02 2014-08-20 로슈 글리카트 아게 Multispecific antibodies comprising full length antibodies and single chain fab fragments
DK2417156T3 (en) 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
PE20120540A1 (en) 2009-05-27 2012-05-09 Hoffmann La Roche THREE-SPECIFIC OR TETRA-SPECIFIC ANTIBODIES
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN101606769A (en) 2009-07-15 2009-12-23 陈德芳 A kind of gemstone connecting structure
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
PL2504364T3 (en) 2009-11-24 2017-12-29 Medimmune Limited Targeted binding agents against b7-h1
CA3220104A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
LT2691417T (en) 2011-03-29 2018-10-25 Roche Glycart Ag Antibody fc variants
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
US9096642B2 (en) 2011-06-08 2015-08-04 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
AU2012298535A1 (en) 2011-08-23 2014-02-06 Roche Glycart Ag Bispecific antigen binding molecules
CN202382282U (en) 2011-09-30 2012-08-15 张伟生 Energy-saving gas stove
BR112014018005B1 (en) 2012-02-15 2021-06-29 F. Hoffmann-La Roche Ag USE OF A NON-COVALENT IMMOBILIZED COMPLEX
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
CN109467601B (en) 2012-05-31 2022-07-08 索伦托药业有限公司 Antigen binding proteins that bind to PD-L1
PE20151807A1 (en) 2013-04-29 2015-12-02 Hoffmann La Roche MODIFIED ANTIBODIES OF BINDING TO HUMAN FCRN AND METHOD OF USE
PT2992017T (en) 2013-05-02 2021-01-29 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
JP6563906B2 (en) 2013-05-31 2019-08-21 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Antigen binding protein that binds to PD-1
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
CN103650585B (en) 2013-07-08 2017-11-21 华为技术有限公司 A kind of method and apparatus of cell switching
SI3363790T1 (en) 2013-09-06 2020-08-31 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
EA029661B1 (en) 2013-09-06 2018-04-30 Ауриген Дискавери Текнолоджиз Лимитед 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
ES2927567T3 (en) 2013-09-13 2022-11-08 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutic and diagnostic products
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
PT3081576T (en) 2013-12-12 2019-10-15 Jiangsu Hengrui Medicine Co Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
KR102597804B1 (en) 2013-12-20 2023-11-07 제넨테크, 인크. Dual specific antibodies
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
EP3686219A1 (en) 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
KR20160108566A (en) 2014-02-04 2016-09-19 화이자 인코포레이티드 Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Multispecific antibodies
US20150379759A1 (en) 2014-06-30 2015-12-31 Jagonal Pty Ltd System and method for rendering buildings in three dimensions
WO2016016299A1 (en) 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Multispecific antibodies
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
KR20170052600A (en) 2014-09-12 2017-05-12 제넨테크, 인크. Cysteine engineered antibodies and conjugates
MA40035A (en) 2014-10-14 2016-04-21 Dana Farber Cancer Inst Inc PD-L1 ANTIBODY MOLECULES AND THEIR USES
US10949507B2 (en) 2014-10-17 2021-03-16 Vulpecula, Llc. Methods, systems, and computer program products for web browsing
WO2016089873A1 (en) 2014-12-02 2016-06-09 Celgene Corporation Combination therapies
CN107787332B (en) 2015-04-24 2022-09-09 豪夫迈·罗氏有限公司 Multispecific antigen binding proteins
AU2020258480A1 (en) * 2019-04-19 2021-10-21 Genentech, Inc. Anti-mertk antibodies and their methods of use

Also Published As

Publication number Publication date
TW202233671A (en) 2022-09-01
WO2022086957A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
ES2523740T3 (en) Monoclonal antibodies to the fibroblast growth factor 2 receptor
PE20211863A1 (en) BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING CLONE 212 ANTI-FAP
AR065506A1 (en) OX40 ANTAGONIST ANTIBODIES AND ITS USE IN THE TREATMENT OF DISEASES
PE20221869A1 (en) BISECIFIC ANTIGEN-BINDING MOLECULES DIRECTED TO OX40 AND PAF
AR110659A1 (en) ANTI-NEUROPILIN ANTIGENS PROTEINS AND METHOD FOR USE
PE20211709A1 (en) ANTIBODIES THAT RECOGNIZE TAU
AR088579A1 (en) FORMULATIONS OF ANTIBODIES
PE20080980A1 (en) ANTI-LYMPHOTOXIN ALPHA ANTIBODIES
PE20141186A1 (en) TNF-ALPHA BINDING PROTEINS
PE20120211A1 (en) ANTIBODIES THAT HAVE HUMAN OX40 SPECIFICITY
RS54197B1 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
AR080243A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT
PE20220279A1 (en) SPECIFIC INHIBITORS OF THE LTBP COMPLEX OF TGF BETA AND USES THEREOF
PE20230844A1 (en) ANTI-NECTIN-4 ANTIBODY, CONJUGATE WHICH INCLUDES IT AND APPLICATION THEREOF
PE20121645A1 (en) COMPOSITIONS AND METHODS TO TREAT INFLAMMATORY DISORDERS
RU2019124709A (en) COMPOSITIONS AND METHODS ASSOCIATED WITH DESIGNED CONSTRUCTIONS BASED ON Fc-ANTIGEN BINDING DOMAIN
RU2018106456A (en) ANTIBODY TO EPHA4
CO6180454A2 (en) ANTIBODIES OF EGFL7 AND METHODS OF USE
PE20240819A1 (en) ANTI-HLA-G ANTIBODIES AND THEIR USE
AR126758A2 (en) ANTI-LY6G6D ANTIBODIES AND METHODS OF USE
AR123855A1 (en) PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE
PE20231504A1 (en) SPECIFIC ANTIBODIES FOR KRAS AND THEIR USES
AR115192A1 (en) ANTIBODIES
AR124558A1 (en) ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
PE20231953A1 (en) MULTI-SPECIFIC ANTIBODIES AND ANTIBODY COMBINATIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure